Search research articles
Contact Us
Filters
Showing results (81-90 of 167) with videos related to
Page
of 17
Sort By:
Cancer Chemotherapy and Pharmacology
|
September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
John Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2021
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S Hong, Kathleen N Moore, Johanna C Bendell, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
October 22, 2024
Improving Patient Understanding and Outcomes in Lung Cancer Using an Animated Patient's Guide with Visual Formats of Learning
Manish R Patel, Abbie Begnaud, Shanda H Blackmon, et al.
Oncotarget
|
October 3, 2015
Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer
Manish R Patel, Blake A Jacobson, Yan Ji, et al.
Targeted Oncology
|
September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N Moore, David S Hong, Manish R Patel, et al.
Eclinicalmedicine
|
April 19, 2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, et al.
The Lancet. Oncology
|
April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes, Jesus G Berdeja, Manish R Patel, et al.
The Oncologist
|
August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study
Johanna Bendell, Sunil Sharma, Manish R Patel, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
Matthew H Taylor, Aung Naing, John Powderly, et al.
Nature Medicine
|
June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 167) with videos related to
Sort By:
Page
of 17
Cancer Chemotherapy and Pharmacology
|
September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
John Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2021
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S Hong, Kathleen N Moore, Johanna C Bendell, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
October 22, 2024
Improving Patient Understanding and Outcomes in Lung Cancer Using an Animated Patient's Guide with Visual Formats of Learning
Manish R Patel, Abbie Begnaud, Shanda H Blackmon, et al.
Oncotarget
|
October 3, 2015
Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer
Manish R Patel, Blake A Jacobson, Yan Ji, et al.
Targeted Oncology
|
September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N Moore, David S Hong, Manish R Patel, et al.
Eclinicalmedicine
|
April 19, 2021
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, et al.
The Lancet. Oncology
|
April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes, Jesus G Berdeja, Manish R Patel, et al.
The Oncologist
|
August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study
Johanna Bendell, Sunil Sharma, Manish R Patel, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
Matthew H Taylor, Aung Naing, John Powderly, et al.
Nature Medicine
|
June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Page
of 17